Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081094 · ClinicalTrials.gov registry record · NA
Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer
A NA study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT00081094 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 31 participants.
The verdict
NCT00081094, a NA study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
RATIONALE: Imaging procedures, such as carbon-11 acetate positron emission tomography (PET) and fludeoxyglucose F 18 PET, may improve the ability to detect hepatocellular carcinoma (liver cancer) and allow doctors to plan the most effective treatment. PURPOSE: This clinical trial is studying how well carbon-11 acetate PET and fludeoxyglucose F 18 PET work in detecting cancer in patients with liver cancer.
Interventions
- PROCEDURE 18F-Fluorodeoxyglucose-PET (FDG-PET)
- PROCEDURE 11Carbon-Acetate-PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2003-09 |
| Est. Completion | 2005-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00081094
The ClinicalTrials.gov registry entry for NCT00081094 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 18F-Fluorodeoxyglucose-PET (FDG-PET) is the first listed.
NCT00081094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00081094 about?
NCT00081094 is a clinical study titled "Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer". RATIONALE: Imaging procedures, such as carbon-11 acetate positron emission tomography (PET) and fludeoxyglucose F 18 PET, may improve the ability to detect hepatocellular carcinoma (liver cancer) and allow doctors to plan the most effective treatment. PURPOSE: This clinical trial is studying how we...
What is the current status of trial NCT00081094?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2003-09. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00081094?
The interventions under investigation include: 18F-Fluorodeoxyglucose-PET (FDG-PET) (PROCEDURE), 11Carbon-Acetate-PET (PROCEDURE).
Who is sponsoring clinical trial NCT00081094?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.